SCHEMBL1714740

SCHEMBL1714740

O=C(NOCc1ccccc1)c1ccccc1NCc1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.52
KMT2A Q03164 5/20 0.52
ALDH1A1 P00352 4/20 0.52
MEN1 O00255 2/20 0.52
ALOX15 P16050 1/20 0.52
KDM4E B2RXH2 3/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 2/20 0.51
HSD17B10 Q99714 1/20 0.51
POLB P06746 2/20 0.51
MAPT P10636 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HTT P42858 1/20 0.49
KDM6B O15054 1/20 0.48
KDM4A O75164 1/20 0.48
KDM4D Q6B0I6 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715384 0.88 KDR (0.52) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL1715363 0.83 KDM4C (0.64) KDM4EKDM6BKDM4AKDM4DKDM4C
SCHEMBL1715783 0.83 KMT2A (0.47) USP2KMT2AALDH1A1MEN1ALOX15
SCHEMBL1715877 0.82 PTGS2 (0.54) KDM4EGAAKDM6BKDM4AKDM4D
SCHEMBL1715462 0.81 PTGS2 (0.46) KMT2AALDH1A1MEN1ALOX15KDM4E
SCHEMBL1715256 0.81 KDM4C (0.54) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL1715406 0.81 KDR (0.53) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL1715301 0.81 NPC1 (0.50) KMT2AMEN1TSHRNPC1RAB9A
SCHEMBL1715827 0.81 NPC1 (0.48) KMT2AALDH1A1ALOX15KDM4EHPGD
SCHEMBL1715108 0.81 L3MBTL1 (0.54) KMT2AALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US claimed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP claimed
CN-1906155-B Novel hydroxamic acid ester derivant and pharmaceutical use thereof LEO PHARMA AS 2010-06-23 CN claimed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
CN-1906155-B Novel hydroxamic acid ester derivant and pharmaceutical use thereof LEO PHARMA AS 2010-06-23 CN disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 USP2 3236/4885KMT2A 1452/4885ALDH1A1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.